sulfasalazine has been researched along with Osteosarcoma in 2 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine (SAS) is an FDA-approved drug for the treatment of Crohn's disease, rheumatoid arthritis, and inflammatory bowel disease." | 5.72 | Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells. ( Liu, J; Lou, C; Lv, H; Shang, P; Wang, Y; Zhen, C, 2022) |
| "Sulfasalazine (SAS) is an FDA-approved drug for the treatment of Crohn's disease, rheumatoid arthritis, and inflammatory bowel disease." | 1.72 | Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells. ( Liu, J; Lou, C; Lv, H; Shang, P; Wang, Y; Zhen, C, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J | 1 |
| Lou, C | 1 |
| Zhen, C | 1 |
| Wang, Y | 1 |
| Shang, P | 1 |
| Lv, H | 1 |
| Preston, SJ | 1 |
| Clifton-Bligh, P | 1 |
| Laurent, MR | 1 |
| Jackson, C | 1 |
| Mason, RS | 1 |
2 other studies available for sulfasalazine and Osteosarcoma
| Article | Year |
|---|---|
Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells.
Topics: Antioxidants; Bone Neoplasms; Cell Line, Tumor; Child; Ferroptosis; Humans; Iron; Osteosarcoma; Reac | 2022 |
Effect of methotrexate and sulphasalazine on UMR 106 rat osteosarcoma cells.
Topics: Alkaline Phosphatase; Animals; Antirheumatic Agents; Bone Neoplasms; Cell Count; Cell Division; Cell | 1997 |